Put the body on offense.

PhosChol: Put the body on offense
March 25, 2017: Nutrasal Partners with Natural Partners…

PhosChol: For the Heart

PhosChol is the Physiological Way to Manage Risk

PhosChol (PPC) interferes at various sites in the pathological processes of dyslipoproteinemia and atherosclerosis by means of its polyunsaturated phosphatidylcholine (PPC) content.

In order to be effective, an anti-hyperlipoproteinemic treatment should act simultaneously on the blood and the vascular walls. The treatment must accordingly aim at improving a pathological lipoprotein pattern as well as reversing existing atherosclerotic changes of the vascular wall. PPC meets this requirement.

PPC restores pathological lipoprotein patterns to normal.

Due to the greater capacity of PPC-enriched HDL (high-density lipoproteins) to take up cholesterol (1), a greater portion of atherogenic cholesterol is converted into a form that can be more readily transported by HDL and which is rapidly metabolized in the liver. By this means, polyunsaturated phosphatidylcholine aids normalization of pathological LDL-cholesterol/HDL-cholesterol ratio, Fig. 1 (2).

Figure 1

PPC reduces elevated blood lipid levels.

In contrast to several other hypolipidemic agents, PPC helps reduce elevated cholesterol and triglyceride levels, Fig. 2 (3,8).

Figure 2

PPC improves blood flow properties.

PPC mobilizes cholesterol and facilitates its removal from arterial walls.

Figure 3

References & Areas of Use

References:

  1. Zierenberg, O., et al., Atherosclerosis 39 (1981), 527.
  2. Zierenberg, O., in: Phospholipids and Atherosclerosis. Raven Press: New York 1983, 175.
  3. Mastellone, I., et al., J. Nutr. Biochem. 11 (2000), 461.
  4. Assmann, G,. in: Phosphatidylcholine. Peeters (Ed.) Springer: Berlin 1976, 34.
  5. Yasugi, T. et al., New Ren Clin. 22. (1973), 691.
  6. Avogaro, P., in: Phospholipids and Atherosclerosis. Raven Press: New York 1983, 211.
  7. Schneider, J,. in: Phospholipids and Atherosclerosis. Raven press: New York 1983, 215.
  8. Zulic, I. et al., Ärztezeitschr. für Naturheilverfahren 39 (1998), 226.

Areas of Use

Dyslipoproteinemia (hypercholesterolemia, hypertriglyceridemia, and hypoalphalipoproteinemia); atherosclerosis; coronary, cerebral, and peripheral circulatory disturbances; angina pectoris; condition following myocardial infarction, and apoplexy; hypertension due to sclerosis; vascular disorders, especially in diabetes mellitus; nephrotic syndrome; pre-operative treatment for the prevention of thromboembolism.

Dosage and Administration:

Unless otherwise prescribed by the physician, 2-3 grams (2-3 capsules or 1 tsp. liquid concentrate) once daily. To be administered during meals with a little liquid if required.